Sugi Predict

Sugi Predict / Targets / CIT

CIT

Citron Rho-interacting kinase · O14578 · CIT on Sugi Atlas →

50,285 patent compounds predicted against CIT, 41,535 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL99683 SCHEMBL99683 0.57 14/20
SCHEMBL101576 SCHEMBL101576 0.50 14/20
SCHEMBL99958 SCHEMBL99958 0.50 9/20
SCHEMBL100699 SCHEMBL100699 0.49 9/20
Nitrous Acid Nitrous Acid (SCHEMBL100612) 0.47 8/20
SCHEMBL99923 SCHEMBL99923 0.46 8/20
SCHEMBL98761 SCHEMBL98761 0.51 5/20
SCHEMBL99011 SCHEMBL99011 0.50 5/20
SCHEMBL99706 SCHEMBL99706 0.48 5/20
SCHEMBL101211 SCHEMBL101211 0.42 5/20
SCHEMBL101331 SCHEMBL101331 0.50 4/20
SCHEMBL101852 SCHEMBL101852 0.46 4/20
SCHEMBL84365 SCHEMBL84365 0.50 3/20
SCHEMBL99870 SCHEMBL99870 0.49 3/20
SCHEMBL99168 SCHEMBL99168 0.48 3/20
SCHEMBL100113 SCHEMBL100113 0.48 3/20
SCHEMBL100267 SCHEMBL100267 0.48 3/20
SCHEMBL102694 SCHEMBL102694 0.47 3/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL99512) 0.46 3/20
SCHEMBL99733 SCHEMBL99733 0.46 3/20

Clinical trials — most relevant to CIT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Signaling Mechanisms and Vascular Function in Diabetes Mellitus PHASE2/PHASE3COMPLETED
Methylene Blue and Microcirculation in Septic Shock PHASE3UNKNOWN
A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma PHASE2UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula PHASE2COMPLETED
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer PHASE2COMPLETED
Immunomodulating Therapy and Improved Vaccination Responses by Cox-2 Inhibitor in HIV-infected Patients PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Glucagon Like Peptide-1 in Remote Ischemic Conditioning nanCOMPLETED
Molecular Markers of Human Sperm Function nanWITHDRAWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Effect Inhaled Nitric Oxide in Adult Liver Transplant nanNOT_YET_RECRUITING
Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle? nanUNKNOWN
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases. nanNOT_YET_RECRUITING
Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CIT binder may also engage these)

ProteinNameSimilarity
E9PSL7 — 1.000 E9PSL7 →
P49025 — 1.000 P49025 →
Q9JHZ4 — 0.984 Q9JHZ4 →
A0PJP4 — 0.981 A0PJP4 →
Q4V328 — 0.981 Q4V328 →
Q3URD3 — 0.980 Q3URD3 →
Q28623 — 0.980 Q28623 →
Q17QG3 — 0.979 Q17QG3 →
Q8C9S4 — 0.978 Q8C9S4 →
Q0IHE5 — 0.978 Q0IHE5 →
Q2QLI6 — 0.977 Q2QLI6 →
Q8VD04 — 0.977 Q8VD04 →
D3ZUQ0 — 0.977 D3ZUQ0 →
Q9C9X0 — 0.977 Q9C9X0 →
Q14BN4 — 0.976 Q14BN4 →
Q9JJC6 — 0.976 Q9JJC6 →
Q5ZLS3 — 0.976 Q5ZLS3 →
Q921C5 — 0.975 Q921C5 →
Q5EBL4 — 0.975 Q5EBL4 →
Q9Y6D9 — 0.974 Q9Y6D9 →
Q8BUK6 — 0.974 Q8BUK6 →
Q8TD16 — 0.974 Q8TD16 →
Q6GQ73 — 0.974 Q6GQ73 →
A2VDP1 — 0.974 A2VDP1 →
Q8BR07 — 0.974 Q8BR07 →
Q68CZ1 — 0.974 Q68CZ1 →
P97817 — 0.974 P97817 →
Q96G01 — 0.974 Q96G01 →
Q8CG73 — 0.974 Q8CG73 →
Q653N3 — 0.973 Q653N3 →